NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection.

Citation metadata

Date: Sept. 12, 2022
From: CMAJ: Canadian Medical Association Journal(Vol. 194, Issue 35)
Publisher: CMA Impact Inc.
Document Type: Article
Length: 610 words
Lexile Measure: 2030L

Document controls

Main content

Article Preview :

1 NVX-CoV2373 (marketed as Nuvaxoid) is a protein-based vaccine against SARS-CoV-2, approved in Canada for adults unable or unwilling to receive an mRNA vaccine

Protein-based vaccines have a long history of use that may make them more acceptable to patients who are hesitant to receive mRNA vaccination. (1) NVX-CoV2373 consists of a recombinant spike protein subunit plus adjuvant. It may also be considered for people who are allergic to components of mRNA vaccines (e.g., polyethylene glycol). (2)

2 NVX-CoV2373 can be used in a primary series of vaccination

NVX-CoV2373 can be administered in a 2-dose primary series or as a heterologous primary series with another approved vaccine against SARS-CoV-2. Doses should be separated by 8 weeks to maximize immune response. (2)

3 NVX-CoV2373 may be offered as a booster

Although not approved by Health Canada for this indication, the National Advisory Committee on Immunizations recommends NVX-CoV2373 as a booster 6 months after any primary series....

Source Citation

Source Citation   

Gale Document Number: GALE|A716601213